BK Viremia in Simultaneous Kidney Pancreas Recipients: Single Center Experience
1Transplant Surgery, The Ohio State University Wexner Medical Center, Columbus, OH
2Nephrology, The Ohio State University Wexner Medical Center, Columbus, OH
3Surgery, The Ohio State University Wexner Medical Center, Columbus, OH.
Meeting: 2018 American Transplant Congress
Abstract number: A354
Keywords: Immunosuppression, Infection, Kidney/pancreas transplantation, Outcome
Session Information
Session Name: Poster Session A: Pancreas and Islet: All Topics
Session Type: Poster Session
Date: Saturday, June 2, 2018
Session Time: 5:30pm-7:30pm
Presentation Time: 5:30pm-7:30pm
Location: Hall 4EF
Introduction: The impact of BK viremia in recipients of simultaneous pancreas and kidney transplantation (SPK) is not well known. We therefore studied the incidence and outcomes of BK viremia in SPK recipients at our center. Methods: This is a retrospective study of all SPK recipients done at our institution between January 2010 and January 2016. All recipients received standard immunosuppression protocol consisting of induction with thymoglobulin and rapid prednisone taper of 5 days. The maintenance immunosuppression consisted of neural and mtor inhibitors, in 5% of patients mtor was replaced by myfortic due to side effects. All pancreatic transplants were performed using systemic venous drainage and primary bladder drainage. Results: 138 recipients were evaluated, 14.5% developed BK viremia. One and three year patient survival in the BK viremia group was 95% and 90% respectively compared to 97.5% and 94% in the remaining group and this was not of statistical significance (P=0.5). One and three year kidney graft survival in the BK viremia group was 85% and 80% respectively compared to 91.5% and 84% in the remaining group and this was not of statistical significance (P=0.34). Ninety-five percent of the patients who developed BK viremia were on mtor inhibitors for maintenance immunosuppression, and 94% of those who didn't were not on mtor (P=0,37). Five percent of the BK viremia group had DJ ureter stent placed at time of transplant compared to 4.2% in the other group and this was not statisticaly significant (P=0.7). The incidence of DGF was zero in both groups. Conclusion: BK viremia occurred in 14.5% of SPK recipients, no protective effect of mtor inhibitors was detected, and BK viremia didn't impact the patients or graft survival in SPK recipients.
CITATION INFORMATION: Alebrahim M., Pelletier R., Rajab A., Bumgardner G., Daloul R., Akateh C., Washburn K., El-Hinnawi A. BK Viremia in Simultaneous Kidney Pancreas Recipients: Single Center Experience Am J Transplant. 2017;17 (suppl 3).
To cite this abstract in AMA style:
Alebrahim M, Pelletier R, Rajab A, Bumgardner G, Daloul R, Akateh C, Washburn K, El-Hinnawi A. BK Viremia in Simultaneous Kidney Pancreas Recipients: Single Center Experience [abstract]. https://atcmeetingabstracts.com/abstract/bk-viremia-in-simultaneous-kidney-pancreas-recipients-single-center-experience/. Accessed May 11, 2025.« Back to 2018 American Transplant Congress